These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
81 related articles for article (PubMed ID: 3874930)
1. Recombinant leukocyte A interferon in B-cell chronic lymphocytic leukemia: in vivo effects on autologous antitumor immunity. Schulof RS; Lloyd MJ; Stallings JJ; Mai D; Phillips TM; Jones GJ; Schechter GP J Biol Response Mod; 1985 Jun; 4(3):310-23. PubMed ID: 3874930 [TBL] [Abstract][Full Text] [Related]
2. Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies. Ozer H; Gavigan M; O'Malley J; Thompson D; Dadey B; Nussbaum-Blumenson A; Snider C; Rudnick S; Ferraresi R; Norred S J Biol Response Mod; 1983; 2(6):499-515. PubMed ID: 6607323 [TBL] [Abstract][Full Text] [Related]
3. Recombinant alpha-2a interferon in treatment of B-chronic lymphocytic leukemia. A preliminary report with emphasis on previously untreated patients in early stage of disease. Molica S; Alberti A Haematologica; 1990; 75(1):75-8. PubMed ID: 2338291 [TBL] [Abstract][Full Text] [Related]
4. [Clinical and laboratory prognostic parameters for leukemic types of chronic lymphoproliferative diseases]. Kardum-Skelin I; Planinc-Peraica A; Ostojić Kolonić S; Radić-Kristo D; Milas M; Vrhovac R; Sustercić D; Minigo H; Jaksić B Acta Med Croatica; 2008 Oct; 62(4):351-64. PubMed ID: 19205412 [TBL] [Abstract][Full Text] [Related]
5. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma. Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077 [TBL] [Abstract][Full Text] [Related]
6. Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells. Kokhaei P; Palma M; Hansson L; Osterborg A; Mellstedt H; Choudhury A Exp Hematol; 2007 Feb; 35(2):297-304. PubMed ID: 17258078 [TBL] [Abstract][Full Text] [Related]
7. [Treatment of hematological malignancies with recombinant leukocyte A interferon (rIFN-alpha A)]. Ohno R; Kodera Y; Ogura M; Murase T; Emi N; Okumura M; Morishita Y; Nagura E; Minami S; Morishima Y Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 1):2531-6. PubMed ID: 6594973 [TBL] [Abstract][Full Text] [Related]
8. Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines. Gitelson E; Hammond C; Mena J; Lorenzo M; Buckstein R; Berinstein NL; Imrie K; Spaner DE Clin Cancer Res; 2003 May; 9(5):1656-65. PubMed ID: 12738718 [TBL] [Abstract][Full Text] [Related]
9. Intraperitoneal recombinant alpha-interferon for "salvage" immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Berek JS; Hacker NF; Lichtenstein A; Jung T; Spina C; Knox RM; Brady J; Greene T; Ettinger LM; Lagasse LD Cancer Res; 1985 Sep; 45(9):4447-53. PubMed ID: 4028027 [TBL] [Abstract][Full Text] [Related]
10. Autologous T cells control B-chronic lymphocytic leukemia tumor progression in human-->mouse radiation chimera. Shimoni A; Marcus H; Dekel B; Shkarchi R; Arditti F; Shvidel L; Shtalrid M; Bucher W; Canaan A; Ergas D; Berrebi A; Reisner Y Cancer Res; 1999 Dec; 59(23):5968-74. PubMed ID: 10606243 [TBL] [Abstract][Full Text] [Related]
11. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies). National Toxicology Program Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204 [TBL] [Abstract][Full Text] [Related]
12. Alpha-interferon treatment of cutaneous T cell lymphoma and chronic lymphocytic leukemia. Foon KA; Bunn PA Semin Oncol; 1986 Dec; 13(4 Suppl 5):35-9. PubMed ID: 3541217 [TBL] [Abstract][Full Text] [Related]
13. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer. Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180 [TBL] [Abstract][Full Text] [Related]
14. Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy. O'Brien S; Kantarjian H; Beran M; Robertson LE; Koller C; Lerner S; Keating MJ Blood; 1995 Aug; 86(4):1298-300. PubMed ID: 7632936 [TBL] [Abstract][Full Text] [Related]
15. Recombinant alpha 2-interferon in the treatment of B chronic lymphocytic leukemia in early stages. Rozman C; Montserrat E; Viñolas N; Urbano-Ispizua A; Ribera JM; Gallart T; Compernolle C Blood; 1988 May; 71(5):1295-8. PubMed ID: 3258768 [TBL] [Abstract][Full Text] [Related]
16. [Treatment of leukemias and lymphomas by interferons: II. Phase II of the trial treatment of chronic lymphoid leukemia by human interferon alpha+]. Misset JL; Mathé G; Gastiaburu J; Goutner A; Dorval T; Gouveia J; Schwarzenberg L; Machover D; Ribaud P; de Vassal F Biomed Pharmacother; 1982 Mar; 36(2):112-6. PubMed ID: 7126777 [TBL] [Abstract][Full Text] [Related]
17. Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid. Poggi A; Venturino C; Catellani S; Clavio M; Miglino M; Gobbi M; Steinle A; Ghia P; Stella S; Caligaris-Cappio F; Zocchi MR Cancer Res; 2004 Dec; 64(24):9172-9. PubMed ID: 15604289 [TBL] [Abstract][Full Text] [Related]
18. Normal T cell colony numbers in untreated patients with chronic lymphocytic leukaemia (CLL). Fernandez LA; MacSween JM; Langley GR Br J Haematol; 1984 May; 57(1):97-104. PubMed ID: 6609714 [TBL] [Abstract][Full Text] [Related]
19. Activated autologous T cells exert an anti-B-cell chronic lymphatic leukemia effect in vitro and in vivo. Di Ianni M; Moretti L; Terenzi A; Bazzucchi F; Del Papa B; Bazzucchi M; Ciurnelli R; Lucchesi A; Sportoletti P; Rosati E; Marconi PF; Falzetti F; Tabilio A Cytotherapy; 2009; 11(1):86-96. PubMed ID: 19153855 [TBL] [Abstract][Full Text] [Related]
20. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy. Merritt RE; Yamada RE; Crystal RG; Korst RJ J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]